Auto-generated from public data. Not the firm's stated position.
p53 appears to focus on early-stage biotech investments in Norway, with a particular emphasis on therapeutic biologics targeting unmet medical needs in areas such as fibrosis and neurodegeneration. Recent portfolio companies suggest a strategy of backing pre-seed and seed-stage firms developing antibody and peptide-based therapeutics, with typical check sizes ranging from €0.1M to €1.5M.
Generated 12 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.